Skip to main content

SLE trends: pulse methylprednisolone followed by low dose steroids is rec by various guidelines. Risk factors for SLE f

Social Author Name
Dr. John Cush
Tweet Content
SLE trends: pulse methylprednisolone followed by low dose steroids is rec by various guidelines. Risk factors for SLE flare after GC withdrawal: high Dz activity, active serology, younger age, shorter remission duration, faster tapering strategy, shorter duration/cessation of https://t.co/g6LaTijOpA

Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytop

Social Author Name
Dr. John Cush
Tweet Content
Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytoplasmic staining. Cytoplasmic - most were reticular, dense fine speckled next. Reticular assoc w/ primary biliary cholangitis (w/ Abs against M2). Dense fine https://t.co/SfBY9BShax

Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in co

Social Author Name
Dr. John Cush
Tweet Content
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/N1BL9Bri3M

A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis ma

Social Author Name
Dr. John Cush
Tweet Content
A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis mainly affects Arabs, Armenians, Jews, & Turks. Hx may date back to 1802 & Heberden. Osler described 11 cases in 1895. 1st clear report 1945 by Siegal 10 pts. https://t.co/m20uO3bOoj

Refractory Renal SLE How to manage class III/IV lupus glomerulonephritis when you run out of options, by Dr. Jack Cush

Social Author Name
Dr. John Cush
Tweet Content
Refractory Renal SLE How to manage class III/IV lupus glomerulonephritis when you run out of options, by Dr. Jack Cush. https://t.co/syOVCEozfA https://t.co/UOY8MkZeX2
Hydroxychloroquine for Everyone
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based on its merit.
Lupus Nephritis 2024 Guidelines

The ACR has published evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis (LN). These are the same guidelines presented at ACR Convergence 2024. 

Lessons Learned from a Lupus Registry: Two sides of one coin? It's Dr. Janet Pope reporting at RheumNow on our special

Social Author Name
Dr. John Cush
Tweet Content
Lessons Learned from a Lupus Registry: Two sides of one coin? It's Dr. Janet Pope reporting at RheumNow on our special lupus edition. I'd like to talk about lessons learned from a Canadian lupus registry. Is it two sides of one coin? https://t.co/IxMZhA1uht https://t.co/PJixCj8d6g

J&J announced results of Phase 3 ICONIC-TOTAL study of qd icotrokinra, an oral IL-23 receptor inhibitor, in 311 ps w

Social Author Name
Dr. John Cush
Tweet Content
J&J announced results of Phase 3 ICONIC-TOTAL study of qd icotrokinra, an oral IL-23 receptor inhibitor, in 311 ps w/ difficult scalp and genital psoriasis (PSO) -success in 57%; skin clearance in 66% & genital psoriasis resp in 77% treated https://t.co/WftyEcDh8u https://t.co/Ydy37Eo0jX
Subscribe to
×